Fenster schließen  |  Fenster drucken

<p align=justify>QIAGEN N.V. Invites You to Join Its 2002 Financial Guidance Call on the Web<p>Corporate-news announcement sent by DGAP.
The sender is solely responsible for the contents of this announcement.
--------------------------------------------------------------------------------<p>QIAGEN N.V. Invites You to Join Its 2002 Financial Guidance Call on the Web<p>VENLO, Netherlands, January 21, 2002 /PRNewswire/ -- In conjunction with
QIAGEN´s 2002 Financial Guidance Conference Call, you are invited to listen to
the call that will be broadcasted live over the Internet on Thursday, January
24th at 9:30 a.m. (EST)/2:30 p.m. (UK)/3:30 p.m. (Continental Europe), with
Metin Colpan, Ph.D., Chief Executive Officer and Peer Schatz, Chief Financial
Officer, both of QIAGEN.<p>What:<p>
QIAGEN -- 2002 Financial Guidance Conference Call
When:
Thursday, January 24th, 2002 at 9:30 a.m. (EST)/ 2:30 p.m. (UK)/
3:30 p.m. (CET)
Where:
www.videonewswire.com/QIAGEN/012402/
How:
Live over the Internet -- Simply log on to the web at the address above
The corresponding presentation slides will be available to download 30 minutes
prior to the start of the call in the investor relations section under
http://www.qiagen.com/aboupdf/QIAGEN_012402.pdf
Contact:
Donald Murphy, Noonan/Russo Communications, 212-696-4455 ext.257
QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the
United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia
and Canada, believes it is the world´s leading provider of innovative enabling
technologies and products for the separation, purification and handling of
nucleic acids. The Company has developed a comprehensive portfolio of more than
320 proprietary, consumable products for nucleic acid separation, purification
and handling, nucleic acid amplification, as well as automated instrumentation,
synthetic nucleic acid products and related services. QIAGEN´s products are sold
in more than 42 countries throughout the world to academic research markets and
to leading pharmaceutical and biotechnology companies. In addition, the Company
is positioning its products for sale into developing commercial markets,
including DNA sequencing and genomics, nucleic acid-based molecular diagnostics,
and genetic vaccination and gene therapy. QIAGEN employs approximately 1,500
people worldwide. Further information on QIAGEN can be found at
http://www.QIAGEN.com.
. (Minimum Requirements to listen to broadcast: The RealPlayer software,
downloadable free from http://www.real.com/products/player/index.html, or The
Windows Media Player, downloadable free from www.microsoft.com and at least a
14.4Kbps connection to the Internet. If you experience problems listening to the
broadcast, send an email to webmaster@vdat.com.)
If you are unable to participate during the live webcast, the call will be
archived at the following URL: www.videonewswire.com/QIAGEN/050801.
CONTACT: Donald Murphy, Noonan/Russo Communications, Inc., 212-696-4455 ext.
257 / Audio: www.videonewswire.com/QIAGEN/050801
end of message, (c)DGAP 21.01.2002
--------------------------------------------------------------------------------
WKN: 901626; ISIN: NL0000240000; Index: NEMAX50
Listed: Neuer Markt in Frankfurt;
Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, München, Hannover und
Stuttgart
212200 Jän 02<p><br><br>Autor: DGAP import (),22:03 21.01.2002</p>
 
aus der Diskussion: DGAP-News: QIAGEN N.V. <NL0000240000> english =
Autor (Datum des Eintrages): ad_hoc  (21.01.02 22:03:02)
Beitrag: 1 von 1 (ID:5391423)
Alle Angaben ohne Gewähr © wallstreet:online